MoonLake Immunotherapeutics CFO Sells Shares
MoonLake's CFO sold shares in a planned transaction, reflecting insider activity.
Key Points
- On June 18, 2026, MoonLake Immunotherapeutics CFO Matthias Bodenstedt sold 2,794 shares valued at $54,762.
- Shares of NasdaqCM:MLTX traded near $19.19, with a 52-week range between $5.95 and $62.75.
- MoonLake's market cap is approximately $1.41 billion, and analysts have a mean price target of $27.62.
On June 18, 2026, Matthias Bodenstedt, the Chief Financial Officer of MoonLake Immunotherapeutics, sold 2,794 shares of the company in a planned transaction. The shares were sold at an average price of $19.60, totaling approximately $54,762.
MoonLake Immunotherapeutics Stock Snapshot
Shares of NasdaqCM:MLTX are trading near $19.19. MoonLake Immunotherapeutics has a market capitalization of about $1.41 billion. The stock has a 52-week low of $5.95 and a high of $62.75. Its 50-day moving average is around $17.88, while the 200-day moving average is approximately $19.01. The company's current ratio is 8.60, with a quick ratio of 7.89, and a debt-to-equity ratio of 39.68.
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology firm based in Zug, Switzerland. The company focuses on developing innovative therapies for inflammatory skin and joint diseases. Its flagship product, Sonelokimab, is a novel treatment targeting IL-17A and IL-17F for conditions like hidradenitis suppurativa and psoriatic arthritis. Founded in 2021, MoonLake is led by CEO Dr. Jorge Santos da Silva and employs around 130 people.
Bottom Line
The recent insider sale by MoonLake's CFO is part of a planned transaction, reflecting routine insider activity. Investors often monitor such transactions to gauge insider sentiment. MoonLake's stock has experienced significant volatility, with a wide 52-week trading range. The company's innovative approach in the biotechnology sector continues to draw attention from analysts and investors.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.